SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark A. Stang who wrote (7993)5/11/1998 6:32:00 PM
From: VLAD  Read Replies (1) of 23519
 
Mark,

If overseas sales can compensate for lower sales during Viagra's release, I think we will do fine. I think we have hit bottom at present levels and I expect the stock price to go up as the script numbers increase. The real question is how many men trying and failing on Viagra will pursue further treatment. Based on refills only declining by 165 from last week I think we can say that MUSE does have a satisfied customer base. Looks like only about 20 to 25% of customers who were regular MUSE patients decided not to refill and try Viagra. I would like to see the new script numbers increase back up to 10,000--if we get up to this level by July, I think it will be smooth sailing from that point on.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News